These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 10650181

  • 1. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity.
    Massi P, Fuzio D, Viganò D, Sacerdote P, Parolaro D.
    Eur J Pharmacol; 2000 Jan 17; 387(3):343-7. PubMed ID: 10650181
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.
    Ihenetu K, Molleman A, Parsons M, Whelan C.
    Eur J Pharmacol; 2003 Mar 19; 464(2-3):207-15. PubMed ID: 12620515
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
    Hough LB, Nalwalk JW, Stadel R, Timmerman H, Leurs R, Paria BC, Wang X, Dey SK.
    J Pharmacol Exp Ther; 2002 Oct 19; 303(1):314-22. PubMed ID: 12235266
    [Abstract] [Full Text] [Related]

  • 4. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM, Wakley AA, Tsutsui KT, Laggart JD.
    J Pharmacol Exp Ther; 2012 Mar 19; 340(3):787-800. PubMed ID: 22182934
    [Abstract] [Full Text] [Related]

  • 5. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat.
    Beaulieu1 P, Bisogno1 T, Punwar S, Farquhar-Smith WP, Ambrosino G, Di Marzo V, Rice AS.
    Eur J Pharmacol; 2000 May 19; 396(2-3):85-92. PubMed ID: 10822060
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
    Lay L, Angus JA, Wright CE.
    Eur J Pharmacol; 2000 Mar 10; 391(1-2):151-61. PubMed ID: 10720647
    [Abstract] [Full Text] [Related]

  • 7. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.
    Maneuf YP, Nash JE, Crossman AR, Brotchie JM.
    Eur J Pharmacol; 1996 Jul 18; 308(2):161-4. PubMed ID: 8840127
    [Abstract] [Full Text] [Related]

  • 8. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine.
    Williams CM, Kirkham TC.
    Pharmacol Biochem Behav; 2002 Jul 18; 71(1-2):333-40. PubMed ID: 11812541
    [Abstract] [Full Text] [Related]

  • 9. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
    Darmani NA.
    Pharmacol Biochem Behav; 2001 Jul 18; 69(1-2):239-49. PubMed ID: 11420092
    [Abstract] [Full Text] [Related]

  • 10. A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice.
    Reche I, Fuentes JA, Ruiz-Gayo M.
    Eur J Pharmacol; 1996 Apr 22; 301(1-3):75-81. PubMed ID: 8773449
    [Abstract] [Full Text] [Related]

  • 11. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
    Järbe TU, Lamb RJ, Liu Q, Makriyannis A.
    Eur J Pharmacol; 2003 Apr 11; 466(1-2):121-7. PubMed ID: 12679148
    [Abstract] [Full Text] [Related]

  • 12. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
    Beardsley PM, Martin BR.
    Eur J Pharmacol; 2000 Jan 03; 387(1):47-53. PubMed ID: 10633159
    [Abstract] [Full Text] [Related]

  • 13. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands.
    Smith SR, Terminelli C, Denhardt G.
    Eur J Pharmacol; 2001 Aug 03; 425(1):73-83. PubMed ID: 11672577
    [Abstract] [Full Text] [Related]

  • 14. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
    Wagner JA, Járai Z, Bátkai S, Kunos G.
    Eur J Pharmacol; 2001 Jul 06; 423(2-3):203-10. PubMed ID: 11448486
    [Abstract] [Full Text] [Related]

  • 15. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
    Anikwue R, Huffman JW, Martin ZL, Welch SP.
    J Pharmacol Exp Ther; 2002 Oct 06; 303(1):340-6. PubMed ID: 12235269
    [Abstract] [Full Text] [Related]

  • 16. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.
    Järbe TU, Liu Q, Makriyannis A.
    Psychopharmacology (Berl); 2006 Jan 06; 184(1):36-45. PubMed ID: 16307294
    [Abstract] [Full Text] [Related]

  • 17. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
    Darmani NA.
    Neuropsychopharmacology; 2001 Feb 06; 24(2):198-203. PubMed ID: 11120402
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.